ALAlphabet Inc.

Institutional investor ยท Portfolio as of Q1 2026

SEC EDGAR SourceSEC Filings

Top Holdings26 positions

Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

CME GROUP INC

3.5M$1B25.6%$325.13-17.81%
1 qtr
New
99

PLANET LABS PBC

35.2M$985.2M24.5%$6.32+291.92%
14 qtrssince 2022-Q4
Increased
69

AST SPACEMOBILE INC

8.9M$741.1M18.5%$24.06+197.26%
5 qtrssince 2025-Q1
Unchanged
0

REVOLUTION MEDICINES INC

3.3M$320.2M8.0%$28.69+604.06%
10 qtrssince 2023-Q4
Decreased
0
ARMARM
ADR

Arm Holdings PLC

2M$296.6M7.4%$53.52+420.65%
11 qtrssince 2023-Q3
Unchanged
0

FRESHWORKS INC

16.2M$130.1M3.2%$15.72-19.35%
14 qtrssince 2022-Q4
Unchanged
0

UIPATH INC

7M$78.1M1.9%$12.71+31.24%
14 qtrssince 2022-Q4
Unchanged
0

TEMPUS AI INC

1.6M$70.1M1.7%$35.00+55.11%
8 qtrssince 2024-Q2
Unchanged
0
3.1M$66.7M1.7%$21.34-31.35%
1 qtr
New
69

GITLAB INC

2.7M$59M1.5%$54.31-20.18%
14 qtrssince 2022-Q4
Unchanged
0

PRIME MEDICINE INC

16.6M$57.6M1.4%$15.14-79.06%
14 qtrssince 2022-Q4
Unchanged
0
3.8M$42.1M1.0%$11.17+211.55%
1 qtr
New
68

MAZE THERAPEUTICS INC

1.4M$41.4M1.0%$11.42+142.25%
5 qtrssince 2025-Q1
Unchanged
0

BRIDGEBIO ONCOLOGY THERAPEUT

2.8M$25.3M0.6%$11.47-19.53%
3 qtrssince 2025-Q3
Unchanged
0

RELAY THERAPEUTICS INC

1.6M$15.6M0.4%$14.94+33.40%
14 qtrssince 2022-Q4
Decreased
0

MONTE ROSA THERAPEUTICS INC

684,275$11.3M0.3%$7.61+108.15%
14 qtrssince 2022-Q4
Decreased
0

VERA THERAPEUTICS INC

241,264$9.7M0.2%$19.35+49.30%
14 qtrssince 2022-Q4
Unchanged
0

SANA BIOTECHNOLOGY INC

2.8M$8.1M0.2%$3.95-7.09%
14 qtrssince 2022-Q4
Unchanged
0

BEAM THERAPEUTICS INC

321,604$7.7M0.2%$39.11-32.22%
14 qtrssince 2022-Q4
Unchanged
0

LYELL IMMUNOPHARMA INC

293,256$5.9M0.1%$69.40-80.20%
14 qtrssince 2022-Q4
Unchanged
0
Showing 20 of 26 results.6 more with Pro.
$4B
AUM
26
Positions
Q1 2026
Filing
Rating ยท 2.5
Quarterly Portfolio Change
-7%Q4'24$1.7B-8%Q1'25$1.6B+35%Q2'25$2.1B+13%Q3'25$2.4B+7%Q4'25$2.6B+56%Q1'26$4B
Activity profile
$ moved ยท Q1'26
New70%Increased22%Decreased3%Exited5%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.4 years
<1Q12%1-4Q8%1-2Y12%2Y+69%

Alphabet Inc. manages $4B across 26 positions as of Q1 2026. Top holdings: CME (25.6%), PL (24.5%), ASTS (18.5%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 2.5/5.0.

Q1 2026 Summary

Active quarter - 3 new positions, 6 exits, 1 increased. Top move: CME (NEW, conviction 99). Portfolio: $4.0B across 26 positions.

Top holdings by portfolio weight

Total AUM$4B
CME25.63%
PL24.53%
ASTS18.46%
RVMD7.97%
ARM7.39%
FRSH3.24%
PATH1.94%
TEM1.75%
PAYP1.66%
GTLB1.47%
Other1.44%

Portfolio allocation by GICS sector

Sectors4
Technology33.52%
Financial Services26.34%
Industrials25.22%
Healthcare14.92%

Behavioral investing profile

7-dimension quality assessment
Solid(2.5 / 5.0)
Track Record60
Conviction37
Concentration100
Upgrade to see all dimensions

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used